190 related articles for article (PubMed ID: 10593129)
21. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Füchtenbusch M; Standl E; Schatz H
Exp Clin Endocrinol Diabetes; 2000; 108(3):151-63. PubMed ID: 10926309
[TBL] [Abstract][Full Text] [Related]
22. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
23. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
24. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
25. Troglitazone. Is it all over?
Wagenaar LJ; Kuck EM; Hoekstra JB
Neth J Med; 1999 Jul; 55(1):4-12. PubMed ID: 10431549
[TBL] [Abstract][Full Text] [Related]
26. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
27. [Preclinical studies of AY4166 (A-4166)].
Kondo N
Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
[No Abstract] [Full Text] [Related]
28. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
29. Troglitazone: a new antihyperglycemic agent.
Vidt DG; Speerhas RA; Reddy SS
Cleve Clin J Med; 1997 May; 64(5):238-40. PubMed ID: 9149473
[TBL] [Abstract][Full Text] [Related]
30. [New drugs].
Sternon J
Rev Med Brux; 2001 Sep; 22(4):A394-400. PubMed ID: 11680207
[TBL] [Abstract][Full Text] [Related]
31. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Samraj GP; Kuritzky L; Quillen DM
Hosp Pract (1995); 2000 Jan; 35(1):123-4, 129-32. PubMed ID: 10645993
[No Abstract] [Full Text] [Related]
32. Learning to use troglitazone.
Riddle MC
Diabetes Care; 1998 Sep; 21(9):1389-90. PubMed ID: 9727881
[No Abstract] [Full Text] [Related]
33. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
34. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
35. New diabetes drug targets insulin resistance.
Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488
[No Abstract] [Full Text] [Related]
36. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
37. [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Brogard JM; Neyrolles N; Andres E; Blicklé JF
Rev Med Interne; 1999 Aug; 20 Suppl 3():371s-378s. PubMed ID: 10480188
[TBL] [Abstract][Full Text] [Related]
38. Insulin secretagogues.
Davies MJ
Curr Med Res Opin; 2002; 18 Suppl 1():s22-30. PubMed ID: 12365816
[TBL] [Abstract][Full Text] [Related]
39. Troglitazone and small low-density lipoprotein in type 2 diabetes.
Hirano T; Yoshino G; Kazumi T
Ann Intern Med; 1998 Jul; 129(2):162-3. PubMed ID: 9669982
[No Abstract] [Full Text] [Related]
40. Efficacy of troglitazone measured by insulin resistance index.
Nagasaka S; Iwamoto Y; Ishikawa S; Kuzuya T; Saito T
Lancet; 1997 Jul; 350(9072):184. PubMed ID: 9250189
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
